Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2228-2230

  Zhanel, George G ^a,b   Mayer, Matthew ^c   Laing, Nancy ^a   Adam, Heather J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTAZIDIME; COLISTIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTAZIDIME; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; TOBRAMYCIN;

EID: 33744477346     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01620-05     Document Type: Article

References (11)

1. Drlica, K. 2003. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52:11-17.
2. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, Y. A. Portnoy, and S. H. Zinner. 2004. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int. J. Antimicrob. Agents 23:451-456.
3. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
4. Fuller, J. D., and D. E. Low. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121.
5. Kucers, A., S. Scrowe, M. L. Grayson, and J. Hoy. 1997. The use of antibiotics: a clinical review of antibacterial, antifungal, and antiviral drugs, 5th ed. Butterworth-Heinemann, Boston, Mass.
6. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Safdar, N., J. Handelsman, and D. G. Maki. 2004. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4:519-527.
8. Smith, H. J., M. Walters, T. Hisanaga, G. G. Zhanel, and D. J. Hoban. 2004. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 48:3954-3958.
9. Van Bambeke, F., J. M. Michot, J. Van Eldere, and P. M. Tulkens. 2005. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11:256-280.
10. Zhanel, G. G., T. Hisanaga, N. Laing, M. DeCorby, K. Nichol, L. Palatnick, J. Johnson, A. Noreddin, G. K. M. Harding, L. E. N. Nicolle, the NAUTICA group, and D. J. Hoban. 2005. Antibiotic resistance in outpatient urinary isolates: results from the North American Urinary Tract Infection Alliance (NAUTICA). Int. J. Antimicrob. Agents 26:380-388.
11. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general study derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.